Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
80.9M
-
Shares change
-
+7.26M
-
Total reported value, excl. options
-
$129M
-
Value change
-
-$21.8M
-
Put/Call ratio
-
0.35
-
Number of buys
-
89
-
Number of sells
-
-73
-
Price
-
$1.59
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q1 2023
215 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2023.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80.9M shares
of 207M outstanding shares and own 39% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (13.4M shares), BlackRock Inc. (4.82M shares), Balyasny Asset Management L.P. (4.77M shares), Meditor Group Ltd (4.4M shares), VANGUARD GROUP INC (4.32M shares), Bellevue Group AG (4.21M shares), ARMISTICE CAPITAL, LLC (3.68M shares), MILLENNIUM MANAGEMENT LLC (3.68M shares), Point72 Asset Management, L.P. (3.6M shares), and PLATINUM INVESTMENT MANAGEMENT LTD (2.58M shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.